Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors - PubMed
7 hours ago
- #Solid tumors
- #BRAF inhibitor
- #Phase I trial
- A phase I study evaluated the novel BRAF inhibitor mosperafenib in patients with BRAF V600-mutant solid tumors.
- Mosperafenib demonstrated a favorable safety profile with no maximum tolerated dose reached and low rates of severe treatment-related adverse events.
- Pharmacokinetic analysis showed linear, time-independent exposure achieving sustained inhibition of pERK above 90%.
- Preliminary clinical activity included an overall response rate of 24.2% with responses in both BRAF inhibitor-naïve and exposed patients.
- Median progression-free survival was 6.4 months in colorectal cancer patients and 3.5 months in melanoma patients.